Managing Early HER2+ mBC: Patient-Centered Approaches and Evolving Treatment Strategies

Opinion
Video

Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.

Video content above is prompted by the following:

  • What have been your care strategies for brain metastasis that are beneficial for the patients and their families.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Anatomical graphic of a person with a tumor in their left breast

First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

Russ Conroy
June 4th 2025
Article

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Graphic of a breast with a tumor.

Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

Bridget Hoyt
May 22nd 2025
Article

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

Line illustration of a breast on a yellow background

How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS
May 16th 2025
Article

The number of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Illustration of two people in lab coats doing work at a desk and at a microscope with a breast icon behind

Avutometinib Triplet Active in Resistant HR+/HER2– Breast Cancer

Jax DiEugenio
May 7th 2025
Article

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.

Anatomic image of a breast

T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

Ashling Wahner
April 23rd 2025
Article